Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alx Oncology Holdings (ALXO) Net Income (2019 - 2023)

Alx Oncology Holdings' Net Income history spans 5 years, with the latest figure at $91.1 million for Q4 2023.

  • For Q4 2023, Net Income rose 397.18% year-over-year to $91.1 million; the TTM value through Dec 2023 reached -$24.7 million, up 80.0%, while the annual FY2025 figure was -$497000.0, 99.63% up from the prior year.
  • Net Income for Q4 2023 was $91.1 million at Alx Oncology Holdings, up from -$51.0 million in the prior quarter.
  • Across five years, Net Income topped out at $91.1 million in Q4 2023 and bottomed at -$51.0 million in Q3 2023.
  • The 5-year median for Net Income is -$15.2 million (2021), against an average of -$12.3 million.
  • The largest annual shift saw Net Income crashed 235.34% in 2020 before it surged 397.18% in 2023.
  • A 5-year view of Net Income shows it stood at -$3.0 million in 2019, then plummeted by 206.88% to -$9.3 million in 2020, then surged by 362.53% to $24.5 million in 2021, then plummeted by 225.28% to -$30.6 million in 2022, then soared by 397.18% to $91.1 million in 2023.
  • Per Business Quant, the three most recent readings for ALXO's Net Income are $91.1 million (Q4 2023), -$51.0 million (Q3 2023), and -$34.5 million (Q2 2023).